tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Zevra Therapeutics: Strategic Focus on Miplyffa Drives Buy Rating Amid Promising Growth Prospects
PremiumRatingsZevra Therapeutics: Strategic Focus on Miplyffa Drives Buy Rating Amid Promising Growth Prospects
1M ago
Zevra Therapeutics Reports Strong Q3 Earnings and Strategic Growth
Premium
Company Announcements
Zevra Therapeutics Reports Strong Q3 Earnings and Strategic Growth
1M ago
Zevra Therapeutics price target lowered to $24 from $29 at Cantor Fitzgerald
Premium
The Fly
Zevra Therapeutics price target lowered to $24 from $29 at Cantor Fitzgerald
1M ago
Is ZVRA a Buy, Before Earnings?
PremiumPre-EarningsIs ZVRA a Buy, Before Earnings?
2M ago
Zevra Therapeutics: Positive Data and European Expansion Drive Buy Rating
Premium
Ratings
Zevra Therapeutics: Positive Data and European Expansion Drive Buy Rating
4M ago
Zevra Therapeutics presents new data on MIPLYFFA
Premium
The Fly
Zevra Therapeutics presents new data on MIPLYFFA
4M ago
CoreWeave reports Q2 beat, Gildan to acquire Hanesbrands: Morning Buzz
PremiumThe FlyCoreWeave reports Q2 beat, Gildan to acquire Hanesbrands: Morning Buzz
4M ago
Zevra Therapeutics: Strong Buy Rating Amid U.S. Growth and EU Market Potential
Premium
Ratings
Zevra Therapeutics: Strong Buy Rating Amid U.S. Growth and EU Market Potential
4M ago
Zevra Therapeutics price target lowered to $18 from $19 at Citizens JMP
Premium
The Fly
Zevra Therapeutics price target lowered to $18 from $19 at Citizens JMP
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100